Solifenacyna w leczeniu zespołu pęcherza nadreaktywnego: skuteczność, bezpieczeństwo i znaczenie diagnostyki klinicznej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2025
Słowa kluczowe:
zespół pęcherza nadreaktywnego, objawy z dolnych dróg moczowych, nykturia, solifenacyna, cholinolityki
##plugins.themes.bootstrap3.article.main##
Abstrakt
Solifenacyna stanowi podstawową opcję terapeutyczną dla pacjentów z zespołem pęcherza nadreaktywnego. Leki cholinolityczne zmniejszają nasilenie parć naglących, liczbę epizodów nietrzymania moczu z parć oraz redukują liczbę mikcji, co ma kluczowe znaczenie dla poprawy jakości życia pacjentów z zespołem pęcherza nadreaktywnego. Dzięki bardziej selektywnemu działaniu solifenacyny na receptory M3 i słabemu powinowactwu do innych receptorów muskarynowych charakteryzuje się ona mniejszym nasileniem działań niepożądanych niż oksybutynina i tolterodyna. Solifenacyna jest stosunkowo dobrze tolerowana także przez osoby w wieku podeszłym.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Ślusarczyk, A. (2025). Solifenacyna w leczeniu zespołu pęcherza nadreaktywnego: skuteczność, bezpieczeństwo i znaczenie diagnostyki klinicznej . Medycyna Faktów , 18(2(67), 283-287. https://doi.org/10.24292/01.MF.0225.17
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ito Y, Oyunzul L, Yoshida A et al. Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice. Eur J Pharmacol. 2009; 615(1-3): 201-6. http://doi.org/10.1016/j.ejphar.2009.04.068.
2. Chapple CR, Khullar V, Gabriel Z et al. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urology. 2008; 54(3): 543-62. http://doi.org/10.1016/j.eururo.2008.06.047.
3. Margulis AV, Linder M, Arana A et al. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. 2018; 13(9): e0204456. http://doi.org/10.1371/journal.pone.0204456.
4. Wallis CJD, Lundeen C, Golda N et al. Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence. Can Urol Assoc J. 2016; 10(7-8): 277-80. http://doi.org/10.5489/cuaj.3526.
5. Chapple CR, Fianu-Jonsson A, Indig M et al. Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg. Eur Urology. 2007; 52(4): 1195-203. http://doi.org/10.1016/j.eururo.2007.05.027.
6. bbDuong V, Iwamoto A, Pennycuff J et al. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021; 32(10): 2693-702. http://doi.org/10.1007/s00192-021-04909-5.
7. Herschorn S, Pommerville P, Stothers L et al. Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin. 2011; 27(2): 375-82. http://doi.org/10.1185/03007995.2010.541433.
8. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61(1): 37-49. http://doi.org/10.1016/S0090-4295(02)02243-4.
9. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-14. http://doi.org/10.1016/j.eururo.2006.09.019.
10. Przydacz M, Golabek T, Dudek P et al. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020; 10(1): 19819. http://doi.org/10.1038/s41598-020-76846-0.
11. Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014; 2(2): 43-49. http://doi.org/10.12954/PI.14045.
12. Gratzke C, Bachmann A, Descazeaud A et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015; 67(6): 1099-109. http://doi.org/10.1016/j.eururo.2014.12.038.
13. Mostafaei H, Salehi-Pourmehr H, Jilch S et al. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2022; 8(4): 1072-89. http://doi.org/10.1016/j.euf.2021.08.011.
14. Nambiar AK, Arlandis S, Bø K et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022; 82(1): 49-59. http://doi.org/10.1016/j.eururo.2022.01.045.
15. Nazir J, Kelleher C, Aballéa S et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. Neurourol Urodyn. 2018; 37(3): 986-96. http://doi.org/10.1002/nau.23413.
16. Przydacz M, Gasowski J, Grodzicki T et al. Lower Urinary Tract Symptoms and Overactive Bladder in a Large Cohort of Older Poles – A Representative Tele-Survey. J Clin Med. 2023; 12(8): 2859. http://doi.org/10.3390/jcm12082859.
17. Nakagawa H, Niu K, Hozawa A et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. 2010; 184(4): 1413-8. http://doi.org/10.1016/j.juro.2010.05.093.
18. Chancellor MB, Lucioni A, Staskin D. Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment. Urology. 2024; 186: 123-9. http://doi.org/10.1016/j.urology.2023.11.033.
19. Wagg A, Dale M, Tretter R et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013; 64(1): 74-81. http://doi.org/10.1016/j.eururo.2013.01.002.
20. Palleschi G, Pastore AL, Maggioni C et al. Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation. World J Urol. 2014; 32(4): 1021-5. http://doi.org/10.1007/s00345-013-1175-3.
21. Zhang L, Cai N, Mo L et al. Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis. Int Urogynecol J. 2025 Feb 14. http://doi.org/10.1007/s00192-024-06029-2.
2. Chapple CR, Khullar V, Gabriel Z et al. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urology. 2008; 54(3): 543-62. http://doi.org/10.1016/j.eururo.2008.06.047.
3. Margulis AV, Linder M, Arana A et al. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. 2018; 13(9): e0204456. http://doi.org/10.1371/journal.pone.0204456.
4. Wallis CJD, Lundeen C, Golda N et al. Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence. Can Urol Assoc J. 2016; 10(7-8): 277-80. http://doi.org/10.5489/cuaj.3526.
5. Chapple CR, Fianu-Jonsson A, Indig M et al. Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg. Eur Urology. 2007; 52(4): 1195-203. http://doi.org/10.1016/j.eururo.2007.05.027.
6. bbDuong V, Iwamoto A, Pennycuff J et al. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021; 32(10): 2693-702. http://doi.org/10.1007/s00192-021-04909-5.
7. Herschorn S, Pommerville P, Stothers L et al. Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin. 2011; 27(2): 375-82. http://doi.org/10.1185/03007995.2010.541433.
8. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology. 2003; 61(1): 37-49. http://doi.org/10.1016/S0090-4295(02)02243-4.
9. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6): 1306-14. http://doi.org/10.1016/j.eururo.2006.09.019.
10. Przydacz M, Golabek T, Dudek P et al. Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study. Sci Rep. 2020; 10(1): 19819. http://doi.org/10.1038/s41598-020-76846-0.
11. Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014; 2(2): 43-49. http://doi.org/10.12954/PI.14045.
12. Gratzke C, Bachmann A, Descazeaud A et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015; 67(6): 1099-109. http://doi.org/10.1016/j.eururo.2014.12.038.
13. Mostafaei H, Salehi-Pourmehr H, Jilch S et al. Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol Focus. 2022; 8(4): 1072-89. http://doi.org/10.1016/j.euf.2021.08.011.
14. Nambiar AK, Arlandis S, Bø K et al. European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. Eur Urol. 2022; 82(1): 49-59. http://doi.org/10.1016/j.eururo.2022.01.045.
15. Nazir J, Kelleher C, Aballéa S et al. Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. Neurourol Urodyn. 2018; 37(3): 986-96. http://doi.org/10.1002/nau.23413.
16. Przydacz M, Gasowski J, Grodzicki T et al. Lower Urinary Tract Symptoms and Overactive Bladder in a Large Cohort of Older Poles – A Representative Tele-Survey. J Clin Med. 2023; 12(8): 2859. http://doi.org/10.3390/jcm12082859.
17. Nakagawa H, Niu K, Hozawa A et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. 2010; 184(4): 1413-8. http://doi.org/10.1016/j.juro.2010.05.093.
18. Chancellor MB, Lucioni A, Staskin D. Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment. Urology. 2024; 186: 123-9. http://doi.org/10.1016/j.urology.2023.11.033.
19. Wagg A, Dale M, Tretter R et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013; 64(1): 74-81. http://doi.org/10.1016/j.eururo.2013.01.002.
20. Palleschi G, Pastore AL, Maggioni C et al. Overactive bladder in diabetes mellitus patients: a questionnaire-based observational investigation. World J Urol. 2014; 32(4): 1021-5. http://doi.org/10.1007/s00345-013-1175-3.
21. Zhang L, Cai N, Mo L et al. Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis. Int Urogynecol J. 2025 Feb 14. http://doi.org/10.1007/s00192-024-06029-2.